Basic Research Funding Opportunities
Basic research is one of the cornerstones of Cure SMA’s research strategy. We believe that continued investigation into the causes and biology of SMA is necessary to grow and improve our drug pipeline.
Each year, our Scientific Advisory Board identifies specific priorities for funding, which are then released in a request for proposals. Once submitted, all proposals are evaluated using an NIH-like scoring system based on both scientific quality and relevance to the Cure SMA research mission.
Cure SMA is pleased to announce that we are accepting grant applications for funding of research projects, under a competitive review by our Scientific Advisory Board (SAB). View the complete SAB roster. Please note that Cure SMA will not release a separate drug discovery RFP in the next twelve months.
The deadline for submission is Friday, September 7, 2018. Basic research and postdoctoral fellowship applications will be judged as two separate pools. We anticipate awarding at least $1,000,000 in total funding comprised of 1-2 postdoctoral fellowship and 5-6 basic research grants. The 5-year historical acceptance rate for research proposals to Cure SMA is 28% with an average of 8 grants awarded per year.
PI Awarded Research Grants: Applications will be accepted for one or two years of funding with a maximum funding level per year of $100,000 and a total award of $200,000 (including 8% overhead) over the duration of the entire project.
Postdoctoral Fellowships: Applications will be accepted for one or two years of funding with a maximum funding level per year of $75,000 and a total award of $150,000 (including 8% overhead) over the duration of the entire fellowship. Please note that a specific postdoctoral fellow to complete the work must be identified at the time of submission.
Cure SMA wants to encourage applications on novel research that will enhance our understanding of SMA disease pathology at the molecular, cellular, and biochemical level; generate key reagents and tools to facilitate drug development and clinical trials; and identify new therapeutic strategies for SMA, in particular combination approaches. Cure SMA welcomes high risk, high reward projects and values the ability to provide seed funding for these types of exploratory projects. Please note that high risk projects are generally not awarded maximum funding without compelling preliminary data.
We envision that studies funded by this Research RFP will fall into one the following key areas:
- Studies focused on the molecular and biochemical mechanisms regulating SMN expression or mediating SMN function. Results should lead to a better understanding of the requirements for SMN protein biologically. There is a particular interest in identifying genetic modifiers, upstream regulators of SMN expression / splicing / function, and downstream effectors of SMN functional activity, resulting in new drug targets for SMA.
- Studies resulting in greater understanding of the pathophysiology of SMA, using well-validated animal or cellular models of the SMA. This includes focus on the tissue or timing requirements for SMN protein, the cellular autonomy of the disease in motor neurons and other cells, peripheral versus central manifestations of SMA, and others.
- Studies focused on early proof-of concept assessment of novel therapeutic approaches for SMA in well-validated animal or cellular models of the disease or on progressing aspects of ongoing preclinical drug programs for SMA towards IND. Proposed SMN enhancing approaches should have advantage over current candidates or have the ability to be used in combination. Particular interest exists in non-SMN based approaches with the potential for combination use with SMN up-regulation strategies.
- Work focused on generating research or clinical trial tools for SMA, such as new animal models, phenotypic cellular assays, activity assays for SMN function, biomarkers or outcome measures for clinical trials, and newborn screening protocols / technologies.
To apply for a basic research grant, please download a copy our grant application form. Please submit an electronic copy as well as 4 hard copies and the original to Cure SMA. The electronic copy should be sent to firstname.lastname@example.org - include the PI’s surname and Basic Research in the subject line. Hard copies should be sent to:
925 Busse Road
Elk Grove Village, IL 60007
All applications are reviewed by our Scientific Advisory Board (SAB), on both scientific quality and relevance to the Cure SMA research mission of accelerating the discovery of safe and effective treatments for SMA.
RFP Release Date: July 16, 2018
Proposal Due Date: September 7, 2018 (midnight ET)
Award Notification: By January 31, 2019
For more information or if you have questions, please contact Jackie Glascock, PhD, Cure SMA Scientific Program Manager at email@example.com.
Since 2004, we've funded nearly $11 million in basic research grants. See more information about our past grants:
- 2016 DOWNLOAD
- 2015 DOWNLOAD
- 2014 DOWNLOAD
- 2013 DOWNLOAD
- 2012 DOWNLOAD
- 2011 DOWNLOAD
- 2010 DOWNLOAD
- 2009 DOWNLOAD
- 2008 DOWNLOAD
- 2007 DOWNLOAD
- 2006 DOWNLOAD
- 2005 DOWNLOAD
- 2004 DOWNLOAD
Jill Jarecki, PhD
Scientific Program Manager
Jackie Glascock, PhD
Elliot J. Androphy, MD, Kampen-Norins Professor and Chair of the Department of Dermatology of Indiana University School of Medicine; SMA Biology.
Arthur H. Burghes, PhD, Professor of Molecular and Cellular Biochemistry at the Ohio State University; SMA Biology and Animal Models.
Tom Crawford, MD, Associate Professor of Neurology and Pediatrics at the Johns Hopkins School of Medicine; Child Neuromuscular Disorders.
Stephen J. Kolb, MD, PhD, Associate Professor of Neurology and Biological Chemistry & Pharmacology, The Ohio State Wexner Medical Center; Molecular Pathology of SMA, Biomarkers, and Clinical Trials.
Rashmi Kothary, PhD, Associate Director and Senior Scientist at the Ottawa Hospital Research Institute and a Professor at the University of Ottawa; SMA Biology and Animal Models.
Adrian Krainer, PhD, Professor at the Cold Spring Harbor Laboratory; SMN splicing.
Umrao Monani, PhD, Associate Professor of Pathology and Cell Biology, Columbia University; SMA Biology and Animal Models.
Samuel Pfaff, PhD, Investigator of the Howard Hughes Medical Institute and Professor at the Gene Expression Laboratory at the Salk Institute for Biological Studies in La Jolla, California; Motor Neuron Biologist.
Mark Rich, MD, PhD, Associate Professor in the Department of Neuroscience, Cell Biology, and Physiology at Wright State University; Neuromuscular Junction Biology.
Kathryn Swoboda, MD, Endowed Chair in Neurogenetics, Neurogenetics Program Director, MGH Neurogenetics Diagnostic Laboratory Co-Director; Child Neuromuscular Disorders.